N@N

iCAD to Participate in Exhibition of Medical Equipment Innovations for U.S. Congress

^{Published on 2010-06-24 06:11:08 - Market Wire}
 

NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced it will be exhibiting at the Medical Equipment Exhibition for U.S. Congress members. The event is sponsored by The Honorable Rep. Edolphus Towns (NY-10^th) and is designed to educate members, staff and the public on new medical technologies.

"As a leader in advanced image analysis solutions, iCAD is focused on continuing its educational initiatives to improve the general understanding of how imaging protocols support earlier cancer detection, better patient care and improved patient outcomes"

The exhibition will take place on Thursday, June 24, 2010 from 11 a.m. a" 3 p.m., at the Rayburn House Office Building, near Independent Avenue and South Capital Street, in the Rayburn Foyer, Level B.

iCAD will be exhibiting aState of the Art Technologya used in the detection and diagnosis of Prostate and Colon Cancers:

• VividLook^®, for prostate cancer detection and diagnosis, is a software package designed to provide the radiologist with powerful tools for processing and analyzing contrast enhanced MR images of the prostate, and to help them distinguish benign from malignant lesions.
• VeraLooka", a Computer-Aided Detection (CAD) technology is designed to support detection of colonic polyps in conjunction with Colon Cancer screening via CT Colonography or aVirtual Colonoscopy*a, the procedure President Obama recently had as part of his annual physical.

aAs a leader in advanced image analysis solutions, iCAD is focused on continuing its educational initiatives to improve the general understanding of how imaging protocols support earlier cancer detection, better patient care and improved patient outcomes,a said Ken Ferry, President and CEO of iCAD. aWe look forward to educating members of Congress and their staffs, and the general public about our technologies, demonstrating their importance in the diagnosis and detection of cancer.a

*Investigational Device. Limited by Federal Law to Investigational Use Only.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). Since receiving FDA approval for the Companya™s first breast cancer detection product in 2002, more than 3,500 iCAD systems have been placed in healthcare practices worldwide. iCADa™s solutions aid in the early detection of the most prevalent cancers including breast and prostate, and in the future colon and lung cancer. For more information, call (877) iCADnow or visit [ www.icadmed.com ].

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companya™s filings with the Securities and Exchange Commission. The words abelieve,a ademonstrate,a aintend,a aexpect,a aestimate,a aanticipate,a alikely,a and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.